R
Richard E. Champlin
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1500
Citations - 73470
Richard E. Champlin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 138, co-authored 1402 publications receiving 66917 citations.
Papers
More filters
Journal ArticleDOI
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
Sergio Giralt,Elihu H. Estey,Maher Albitar,Koen van Besien,Gabriela Rondon,Paolo Anderlini,Susan O'Brien,Issa F. Khouri,James Gajewski,Rakesh Mehra,David F. Claxton,Borje S. Andersson,Miloslav Beran,Donna Przepiorka,Charles Koller,Steve Kornblau,Martin Korbling,Michael J. Keating,Hagop M. Kantarjian,Richard E. Champlin +19 more
TL;DR: It is concluded that purine analog-containing nonmyeloablative regimens allow engraftment of HLA-compatible hematopoietic progenitor cells and warrants further study in patients with leukemia who are ineligible for conventional transplantation with myeloablatives either because of age or concurrent medical conditions.
Journal ArticleDOI
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu,David Marin,Pinaki P. Banerjee,Homer A. Macapinlac,Philip A. Thompson,Rafet Basar,Lucila Nassif Kerbauy,Bethany J Overman,Peter F. Thall,Mecit Kaplan,Vandana Nandivada,Indresh Kaur,Ana Karen Nunez Cortes,Kai Cao,May Daher,Chitra Hosing,Evan N. Cohen,Partow Kebriaei,Rohtesh S. Mehta,Sattva S. Neelapu,Yago Nieto,Michael Wang,William G. Wierda,Michael J. Keating,Richard E. Champlin,Elizabeth J. Shpall,Katayoun Rezvani +26 more
TL;DR: Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects.
Journal Article
Bone Marrow-derived Mesenchymal Stem Cells as Vehicles for Interferon-β Delivery into Tumors
Matus Studeny,Frank C. Marini,Richard E. Champlin,Claudia Zompetta,Isaiah J. Fidler,Michael Andreeff +5 more
TL;DR: It is demonstrated that, for the purpose of anticancer therapy, bone marrow-derived mesenchymal stem cells (MSCs) can produce biological agents locally at tumor sites and that the tumor microenvironment preferentially promotes the engraftment of MSCs as compared with other tissues.
Journal ArticleDOI
Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents
Matus Studeny,Frank C. Marini,Jennifer L. Dembinski,Claudia Zompetta,Maria Cabreira-Hansen,Benjamin N. Bekele,Richard E. Champlin,Michael Andreeff +7 more
TL;DR: Injected MSC-IFN-beta cells suppressed the growth of pulmonary metastases, presumably through the local production of IFN- beta in the tumor microenvironment, and may be an effective platform for the targeted delivery of therapeutic proteins to cancer sites.
Journal ArticleDOI
Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells.
Martin Korbling,Ruth L. Katz,Abha Khanna,Arnout C.C. Ruifrok,Gabriela Rondon,Maher Albitar,Richard E. Champlin,Zeev Estrov +7 more
TL;DR: All six recipients of sex-mismatched transplants showed evidence of complete hematopoietic donor chimerism and the presence of donor cells in the biopsy specimens did not seem to depend on the intensity of tissue damage induced by graft-versus-host disease.